GlassScriptPhysician profile
Kaitlyn Breiten
NPI 1770147977
$2,267.02
in general payments reported to CMS, 2019-2025
26 companies · $569 in 2025
The $569 reported for 2025 was more than what 89% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $414 · 2022: $306 · 2023: $540 · 2024: $438 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.23 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $703.91 | 2021-2025 | |
| Aspira Women'S Health INC | $272.73 | 2021-2023 | Ova1 |
| Astellas Pharma US INC | $184.95 | 2022-2023 | |
| Gilead Sciences, INC. | $170.79 | 2023-2025 | Epclusa |
| Exact Sciences Corporation | $169.02 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $152.81 | 2024-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $64.76 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $63.12 | 2023-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $60.99 | 2022-2025 | Mounjaro, Zepbound |
| Indivior INC. | $53.88 | 2024-2025 | Sublocade |
| Therapeuticsmd, INC. | $41.56 | 2021 | |
| Agile Therapeutics, INC. | $39.84 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.45 | 2023-2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $37.09 | 2021 | |
| Exeltis, USA INC. | $30.49 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $29.40 | 2023 | Rexulti, Abilify Maintena |
| Daiichi Sankyo INC. | $23.39 | 2022 | |
| Organon LLC | $19.52 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.65 | 2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $14.91 | 2024 | Breztri |
| Shield Therapeutics INC | $14.43 | 2024 | |
| Avion Pharmaceuticals | $14.22 | 2021 | |
| Coopersurgical, INC. | $13.86 | 2021 | |
| Hologic Sales and Service, LLC | $12.65 | 2021 | |
| Evofem Biosciences, INC. | $12.49 | 2021 | |
| Mylan Pharmaceuticals INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Breiten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.